QUECTEL-WIRELESS
21.6.2022 11:02:13 CEST | Business Wire | Press release
Quectel Wireless Solutions has launched the new BG773A-GL ultra-compact LTE Cat M1, NB1 and NB2 module which offers integrated SIM (iSIM) support. The iSIM capability of this new module provides huge flexibility and simplicity for integrators and IoT service providers because, in essence, it enables a device with a single stock-keeping unit (SKU) number to have the right connectivity to support its needs globally. Ultimately, this provides a simpler way for integrators to adopt cellular connectivity, removing the needs for country-specific SIM cards and simplifying the logistics of traditional, plastic SIM deployments by eradicating the need for on-site or in-country adaptations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005267/en/
Quectel has been at the forefront of making the promise of iSIM a reality and has been working to tightly align module performance with the new wave of embedded and integrated SIM features that are revolutionizing what is possible in IoT connectivity.
The BG773A-GL module also features ultra-low power consumption implemented by the MIPS 5150 processor and integrated RAM and flash, which help reduce current consumption to low levels in various modes, including power saving mode (PSM) and extended discontinuous reception (eDRX). Importantly, the BG773A-GL boasts a comprehensive hardware-based security feature - Integrated Security Elements (ISE). This is essential because iSIM relies on having a robust secure element to enable it to connect to the best available connectivity at the point of deployment. The module will be commercially available from mid July 2022.
“We’re delighted to have launched the Quectel BG773A-GL module which brings iSIM-enabled connectivity to the global marketplace,” says Richard Hart, Director of Global Connectivity, Quectel Connectivity Solutions . “By enabling integrators to create a single global product with one SKU, logistics and supply chain issues are eliminated and IoT organizations can simply deploy their products anywhere safe in the knowledge that they will be able to access secure, high-quality connectivity with no need for localization and different variants to be manufactured for different markets. This is a giant leap forward for simplifying IoT and one of the key steps needed to build a smarter world.”
The module offers an ultra-compact SMT form factor of 14.9 mm × 12.9 mm × 1.9 mm and enables integrators and developers to design applications easily taking advantage of its low power consumption and compact design structure. The BG773A-GL’s industry-standard interfaces and abundant functionalities extend the suitability of the module to a wide range of IoT applications, such as wireless POS, smart metering, tracking, wearable devices, and many others.
Quectel has collaborated with Kigen , the iSIM pioneer and global security leader to enable the iSIM functionality on BG773A-GL. Kigen’s industry-leading iSIM OS and key insertion services bring a wide selection of networks that augment Quectel connectivity for OEMs to meet their market needs.
“Quectel’s adoption of Kigen iSIM as a pre-packaged solution in the BG773A-GL is a testimony to the maturity of iSIM technology and our ecosystem,” said Vincent Korstanje, CEO of Kigen. “Quectel is a market leader in high-volume manufacturing, and this collaboration will enable OEMs who want to move quickly from pure embedded play to offering full IoT solutions for global markets.”
For a live demonstration of the Quectel iSIM, visit Quectel on Booth No 171, Hall 5 at Embedded World Nuremberg, June 21- 23 2022.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.quectel.com , LinkedIn , Facebook and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005267/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom